{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:16:47Z","timestamp":1792894607202,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T00:00:00Z","timestamp":1519689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Chinese medicine Qiliqiangxin (QL) has been shown to have a protective role in heart failure. Here, we explore the underlying working mechanism of the key therapeutic component in QL using a rat model of heart failure. Heart failure after myocardial infarction was induced surgically and confirmed using echocardiography; a separate group of rats underwent sham surgery. The rats with heart failure were randomly assigned to receive QL, the angiotensin-converting enzyme inhibitor benazepril, or placebo groups. Blood samples were collected from the rats at four time points for up to 8 weeks and used for biochemical analysis and mass spectrometry\u2012based metabolomics profiling. In total, we measured nine well-known biochemical parameters of heart failure and 147 metabolites. In the rats with heart failure, QL significantly improved these biochemical parameters and metabolomics profiles, significantly increasing the cardioprotective parameter angiopoietin-like 4 and significantly lowering inflammation-related oxylipins and lysophosphatidic acids compared to benazepril. Mechanistically, QL may improve outcome in heart failure by controlling inflammatory process and cardiac hypertrophy. Clinical studies should be designed in order to investigate these putative mechanisms in patients.<\/jats:p>","DOI":"10.1038\/s41598-018-22074-6","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T11:03:04Z","timestamp":1519210984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach"],"prefix":"10.1038","volume":"8","author":[{"given":"Junzeng","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-4295","authenticated-orcid":false,"given":"Amy C.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hankemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"22074_CR1","first-page":"403","volume":"51","author":"MS Figueroa","year":"2006","unstructured":"Figueroa, M. S. & Peters, J. I. Congestive heart failure: diagnosis, pathophysiology, therapy, and implications for respiratory care. Respir Care 51, 403\u2013412 (2006).","journal-title":"Respir Care"},{"key":"22074_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","volume":"18","author":"EES Van Riet","year":"2016","unstructured":"Van Riet, E. E. S. et al. Epidemiology of heart failure: The prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur. J. Heart Fail. 18, 242\u2013252 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"22074_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMp1410241","volume":"371","author":"CA Sacks","year":"2014","unstructured":"Sacks, C. A., Jarcho, J. A. & Curfman, G. D. Paradigm shifts in heart-failure therapy \u2014 a timeline. N. Engl. J. Med. 371, 989\u2013991 (2014).","journal-title":"N. Engl. J. Med."},{"key":"22074_CR4","first-page":"927160","volume":"2015","author":"L Luo","year":"2015","unstructured":"Luo, L. et al. Chinese herbal medicine in the treatment of chronic heart failure: three-stage study protocol for a randomized controlled trial. Evid. Based. Complement. Alternat. Med. 2015, 927160 (2015).","journal-title":"Evid. Based. Complement. Alternat. Med."},{"key":"22074_CR5","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1055\/s-0030-1250450","volume":"76","author":"J van der Greef","year":"2010","unstructured":"van der Greef, J. et al. Systems biology-based diagnostic principles as pillars of the bridge between Chinese and Western medicine. Planta Med. 76, 2036\u20132047 (2010).","journal-title":"Planta Med."},{"key":"22074_CR6","first-page":"S10","volume":"346","author":"Y Schroen","year":"2014","unstructured":"Schroen, Y. et al. East is East and West is West, and never the twain shall meet? Science. 346, S10\u2013S12 (2014).","journal-title":"Science."},{"key":"22074_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/157489309789071129","volume":"4","author":"S Li","year":"2009","unstructured":"Li, S. Network Systems underlying Traditional Chinese Medicine syndrome and herb formula. Curr. Bioinform. 4, 188\u2013196 (2009).","journal-title":"Curr. Bioinform."},{"key":"22074_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep08374","volume":"5","author":"L Tao","year":"2015","unstructured":"Tao, L. et al. Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice. Sci. Rep. 5, 8374 (2015).","journal-title":"Sci. Rep."},{"issue":"E26","key":"22074_CR9","first-page":"3","volume":"98","author":"Y Zou","year":"2012","unstructured":"Zou, Y. et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodelling, and dysfunction during 4 weeks of pressure overload in mice. Heart 98(E26), 3\u2013E27 (2012).","journal-title":"Heart"},{"key":"22074_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","volume":"113","author":"T Doenst","year":"2013","unstructured":"Doenst, T., Nguyen, T. D. & Abel, E. D. Cardiac metabolism in heart failure. Circ. Res. 113, 709\u2013724 (2013).","journal-title":"Circ. Res."},{"key":"22074_CR11","first-page":"17319","volume":"2","author":"HR Griffiths","year":"2015","unstructured":"Griffiths, H. R. et al. Oxidative stress and microRNAs in vascular diseases. Free Radic. Biol. Med. 2, 17319\u201317346 (2015).","journal-title":"Free Radic. Biol. Med."},{"key":"22074_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/hrt.2002.007005","volume":"90","author":"SD Anker","year":"2004","unstructured":"Anker, S. D. Inflammatory mediators in chronic heart failure: an overview. Heart 90, 464\u2013470 (2004).","journal-title":"Heart"},{"key":"22074_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11306-010-0219-6","volume":"7","author":"MM Koek","year":"2011","unstructured":"Koek, M. M. et al. Semi-automated non-target processing in GC\u2009\u00d7\u2009GC-MS metabolomics analysis: applicability for biomedical studies. Metabolomics 7, 1\u201314 (2011).","journal-title":"Metabolomics"},{"key":"22074_CR14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00216-012-6226-x","volume":"404","author":"K Strassburg","year":"2012","unstructured":"Strassburg, K. et al. Quantitative profiling of oxylipins through comprehensive LC-MS\/MS analysis: application in cardiac surgery. Anal. Bioanal. Chem. 404, 1413\u201326 (2012).","journal-title":"Anal. Bioanal. Chem."},{"key":"22074_CR15","doi-asserted-by":"publisher","unstructured":"Fu, J. et al. Metabolomics profiling of the free and total oxidised lipids in urine by LC-MS\/MS: application in patients with rheumatoid arthritis. Anal. Bioanal. Chem. https:\/\/doi.org\/10.1007\/s00216-016-9742-2 (2016).","DOI":"10.1007\/s00216-016-9742-2"},{"key":"22074_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","volume":"32","author":"G Sayer","year":"2014","unstructured":"Sayer, G. & Bhat, G. The Renin-Angiotensin-Aldosterone System and Heart Failure. Cardiol. Clin. 32, 21\u201332 (2014).","journal-title":"Cardiol. Clin."},{"key":"22074_CR17","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1536\/ihj.46.867","volume":"46","author":"J-H Hsu","year":"2005","unstructured":"Hsu, J.-H., Yeh, J.-L., Dai, Z.-K., Chen, I.-J. & Wu, J.-R. Increased circulating calcitonin gene-related peptide in congestive heart failure caused by congenital heart disease. Int. Heart J. 46, 867\u2013875 (2005).","journal-title":"Int. Heart J."},{"key":"22074_CR18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","volume":"1","author":"SR Goldsmith","year":"1983","unstructured":"Goldsmith, S. R., Francis, G. S., Cowley, A. W., Levine, T. B. & Cohn, J. N. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1, 1385\u20131390 (1983).","journal-title":"J. Am. Coll. Cardiol."},{"key":"22074_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0002-9149(97)00804-7","volume":"81","author":"J Lommi","year":"1998","unstructured":"Lommi, J., Kupari, M. & Yki-J\u00e4rvinen, H. Free Fatty acid kinetics and oxidation in congestive heart failure. Am. J. Cardiol. 81, 45\u201350 (1998).","journal-title":"Am. J. Cardiol."},{"key":"22074_CR20","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1073\/pnas.0307446101","volume":"101","author":"R Radi","year":"2004","unstructured":"Radi, R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc. Natl. Acad. Sci. USA 101, 4003\u20138 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"22074_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbrc.2013.11.013","volume":"441","author":"E Makoveichuk","year":"2013","unstructured":"Makoveichuk, E., Vorrsj\u00f6, E., Olivecrona, T. & Olivecrona, G. Inactivation of lipoprotein lipase in 3T3-L1 adipocytes by angiopoietin-like protein 4 requires that both proteins have reached the cell surface. Biochem. Biophys. Res. Commun. 441, 941\u2013946 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"22074_CR22","first-page":"1","volume":"2015","author":"CE Rupert","year":"2015","unstructured":"Rupert, C. E. & Coulombe, K. L. K. The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark. Insights 2015, 1\u20139 (2015).","journal-title":"Biomark. Insights"},{"key":"22074_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ijcard.2008.11.013","volume":"135","author":"E Eleuteri","year":"2009","unstructured":"Eleuteri, E. et al. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int. J. Cardiol. 135, 386\u2013390 (2009).","journal-title":"Int. J. Cardiol."},{"key":"22074_CR24","doi-asserted-by":"publisher","first-page":"e0157035","DOI":"10.1371\/journal.pone.0157035","volume":"11","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Serum-based oxylipins are associated with outcomes in primary prevention implantable cardioverter defibrillator patients. PLoS One 11, e0157035 (2016).","journal-title":"PLoS One"},{"key":"22074_CR25","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1194\/jlr.E037887","volume":"54","author":"AJ Morris","year":"2013","unstructured":"Morris, A. J. & Smyth, S. S. Lysophosphatidic acid and cardiovascular disease: seeing is believing. J. Lipid Res. 54, 1153\u20135 (2013).","journal-title":"J. Lipid Res."},{"key":"22074_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.tips.2005.04.003","volume":"26","author":"P Pacher","year":"2005","unstructured":"Pacher, P., Schulz, R., Liaudet, L. & Szab\u00f3, C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol. Sci. 26, 302\u2013310 (2005).","journal-title":"Trends Pharmacol. Sci."},{"key":"22074_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.bbalip.2008.05.002","volume":"1781","author":"Y Fujiwara","year":"2008","unstructured":"Fujiwara, Y. Cyclic phosphatidic acid \u2014 A unique bioactive phospholipid. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1781, 519\u2013524 (2008).","journal-title":"Biochim. Biophys. Acta - Mol. Cell Biol. Lipids"},{"key":"22074_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(98)06423-X","volume":"353","author":"HP Hermann","year":"1999","unstructured":"Hermann, H. P. et al. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet (London, England) 353, 1321\u20131323 (1999).","journal-title":"Lancet (London, England)"},{"key":"22074_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.116.005066","volume":"6","author":"LC Gormsen","year":"2017","unstructured":"Gormsen, L. C. et al. Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: A positron emission tomography study. J. Am. Heart Assoc. 6, 1\u201312 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"22074_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11897-013-0131-2","volume":"10","author":"P Detopoulou","year":"2013","unstructured":"Detopoulou, P., Nomikos, T., Fragopoulou, E., Chrysohoou, C. & Antonopoulou, S. Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy. Curr. Heart Fail. Rep. 10, 122\u2013129 (2013).","journal-title":"Curr. Heart Fail. Rep."},{"key":"22074_CR31","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.2174\/138161208786071227","volume":"14","author":"G Marazzi","year":"2008","unstructured":"Marazzi, G., Rosanio, S., Caminiti, G., Dioguardi, F. S. & Mercuro, G. The role of amino acids in the modulation of cardiac metabolism during ischemia and heart failure. Curr. Pharm. Des. 14, 2592\u20132604 (2008).","journal-title":"Curr. Pharm. Des."},{"key":"22074_CR32","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.fct.2008.05.013","volume":"46","author":"Y Tada","year":"2008","unstructured":"Tada, Y. et al. Toxic effects of L-aspartic acid at high dose levels on kidneys and salivary glands in Fischer 344 rats detected in a 90-day feeding study. Food Chem. Toxicol. 46, 2789\u20132795 (2008).","journal-title":"Food Chem. Toxicol."},{"key":"22074_CR33","doi-asserted-by":"crossref","unstructured":"Michal, G. & Schomburg, D. Biochemical Pathways: an atlas of biochemistry and molecular biology (Wiley, 2012).","DOI":"10.1002\/9781118657072"},{"key":"22074_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.prostaglandins.2009.02.002","volume":"91","author":"ME Lin","year":"2010","unstructured":"Lin, M. E., Herr, D. R. & Chun, J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91, 130\u2013138 (2010).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"22074_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10456-008-9113-5","volume":"11","author":"CM Rivera-Lopez","year":"2008","unstructured":"Rivera-Lopez, C. M., Tucker, A. L. & Lynch, K. R. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11, 301\u2013310 (2008).","journal-title":"Angiogenesis"},{"key":"22074_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCRESAHA.114.300507","volume":"114","author":"T Oka","year":"2014","unstructured":"Oka, T., Akazawa, H., Naito, A. T. & Komuro, I. Angiogenesis and cardiac hypertrophy: Maintenance of cardiac function and causative roles in heart failure. Circ. Res. 114, 565\u2013571 (2014).","journal-title":"Circ. Res."},{"key":"22074_CR37","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","volume":"383","author":"G Heusch","year":"2014","unstructured":"Heusch, G. et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383, 1933\u20131943 (2014).","journal-title":"Lancet"},{"key":"22074_CR38","doi-asserted-by":"publisher","first-page":"8440","DOI":"10.1021\/bi9816756","volume":"38","author":"G Gueguen","year":"1999","unstructured":"Gueguen, G. et al. Structure\u2212activity analysis of the effects of lysophosphatidic acid on platelet aggregation. Biochemistry 38, 8440\u20138450 (1999).","journal-title":"Biochemistry"},{"key":"22074_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S. & Stanley, W. C. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90, 207\u2013258 (2010).","journal-title":"Physiol. Rev."},{"key":"22074_CR40","first-page":"91","volume":"59","author":"M Szpetnar","year":"2004","unstructured":"Szpetnar, M., Pasternak, K. & Boguszewska, A. Branched chain amino acids (BCAAs) in heart diseases (ischaemic heart disease and myocardial infarction). Ann. Univ. Mariae Curie. Sklodowska. Med. 59, 91\u20135 (2004).","journal-title":"Ann. Univ. Mariae Curie. Sklodowska. Med."},{"key":"22074_CR41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fendo.2014.00004","volume":"5","author":"G Santulli","year":"2014","unstructured":"Santulli, G. Angiopoietin-like proteins: A comprehensive look. Front. Endocrinol. (Lausanne). 5, 5\u201310 (2014).","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"Suppl. IV","key":"22074_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/clc.4960141805","volume":"14","author":"M Macnab","year":"1991","unstructured":"Macnab, M. & Mallows, S. Safety Profile of benazepril in essential-hypertension. Clin. Cardiol 14(Suppl. IV), 33\u201337 (1991).","journal-title":"Clin. Cardiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22074-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22074-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22074-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:54:14Z","timestamp":1671591254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-22074-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["22074"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-22074-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"6 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3688"}}